Article

Carl Zeiss Meditec to acquire Laser Diagnostic Technologies

Carl Zeiss Meditec Inc. and Laser Diagnostic Technologies Inc. (LDT) announced that they have signed a definitive agreement for Carl Zeiss Meditec's acquisition of LDT.

New Orleans-Carl Zeiss Meditec Inc. and Laser Diagnostic Technologies Inc. (LDT) announced that they have signed a definitive agreement for Carl Zeiss Meditec's acquisition of LDT.

"This acquisition is another important milestone of our growth strategy," said Jim Taylor, president and chief executive officer of Carl Zeiss Meditec Inc. "It will further strengthen our technology portfolio and undisputed leadership in the growing market of glaucoma diagnosis and management. Looking forward, we will continue our aggressive growth through pursuit of both internal and external potentials."

LDT President and CEO John Moore noted that this deal is a reflection of the successful evolution of the company's GDx technology.

"We are pleased by the response of our customers to these recent advances, and this enthusiastic acceptance validates the hard work of our entire LDT team," Moore said. "We expect ongoing adoption and utilization of this technology, especially with the support and capabilities of the Carl Zeiss Meditec organization. I believe that this merger is in the best interests of LDT's customers and shareholders."

LDT invented and commercialized a new standard for glaucoma detection with its proprietary ocular nerve fiber measurement instrument. Worldwide sales of about (U.S.) $20 million with a break-even operating result are expected.

LDT's main product GDx VCC is a dedicated glaucoma diagnosis and management tool that complements the market presence of Carl Zeiss Meditec's StratusOct, which is a multipurpose retinal imaging system used not only for the diagnosis of glaucoma, but also for a wide array of conditions including age-related macular degeneration, diabetic retinopathy and pre-and post-cataract assessment. The GDx VCC targets especially at customers who do not require the full range of capacities as offered by the StratusOct.

The acquisition also addresses trends in the eye-care market by responding to practitioners' desires for more comprehensive solution sets. For glaucoma, this requires measures of both structure and function. Carl Zeiss Meditec provides a complete line of functional diagnostic products, including the Humphrey Matrix and Humphrey Field Analyzer, which is recognized as the standard of care for diagnosis and management of glaucoma through measurement and tracking of changes in the visual field. Through the acquisition Carl Zeiss Meditec now offers the most comprehensive line of both structural and functional assessment tools for the diagnosis and management of glaucoma.

The transaction is expected to close in about 30 to 45 days, pending the requisite company and shareholder approvals. Further details of the agreement were not yet disclosed.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.